Nektar Therapeutics will announce its financial results for the fourth quarter and year-ended December 31, 2017, on Thursday, March 1, 2018, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/ 2:00 p.m. Pacific
AbbVie, a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc., announced that the Phase 3 ELARIS UF-I study of elagolix met its primary endpoint. Uterine fibroids are the most common type of abnormal growth in a woman's pelvis and can affect up to 80 percent of women by age 50. 1 Fibro
AbbVie has teamed up with Voyager Therapeutics on a tau protein-targeting program, paying $69 million upfront for an option on the Alzheimers disease candidate. According to AbbVie, that approach would have dosing advantages over current tau-targeting drugs in the industrys pipeline that could translate into a higher chance of showing efficacy.
BARCELONA, Catalonia, Spain- Ability Pharmaceuticals SL, a biopharmaceutical company announced today that the United States Food and Drug Administration has approved a phase 1/ 2 study to assess the efficacy and safety of ABTL0812 in combination with gemcitabine and nab-paclitaxel in patients with advanced metastatic pancreatic cancer at first line
SAN DIEGO- ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2017 on Tuesday, February 27,
BOTHELL, Washington and VANCOUVER- Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced preliminary data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics clinical study of cytisine.
By a News Reporter-Staff News Editor at Biotech Week Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 15 at 1:30pm EST. A live audio webcast of the presentation can be accessed under "Investor Events" in the Investor section of the
Four months after DBV Technologies stock was crushed by a shaky set of pivotal data for its peanut allergy drug, rival Aimmune Therapeutics$ AIMT says its Phase III has come through with a promising set of results. And the win sets up an FDA application later this year for the pioneering drug, with a European pitch to follow soon after. Its great t
Aldeyra Therapeutics, Inc., a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that the results of the Phase 2 a clinical trial of topical ocular reproxalap in dry eye disease were selected for podium presentation at the 2018 Association for Rese
Arix Bioscience plc, a global healthcare and life science company supporting medical innovation, and Ipsen, a global specialty-driven biopharmaceutical company focused on innovation and specialty care, today announced a strategic agreement to develop and commercialise innovative therapies. Arix will provide Ipsen with access to its unique network o
COPENHAGEN, Denmark- Ascendis Pharma A/S, a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares, each of which represents one ordinary share of Ascendis. J.P. Morgan Securities LLC, BofA Merrill Lynch and Credit Suisse Securities LLC are acting
-Ascendis Pharma A/S, a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares, each of which represents one ordinary share of Ascendis. J.P. Morgan Securities LLC, BofA Merrill Lynch and Credit Suisse Securities LLC are acting as joint book-runni
ROCKVILLE, Md. and HONG KONG, Feb. 21, 2018/ PRNewswire-USNewswire/ Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the presentation of preliminary data from its ongoing Phase 1 trials of its lead product candidate APG-1252, a
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration has approved Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Avid Bioservices, Inc., a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that Enzyvant, a subsidiary of Roivant Sciences, has selected Avid as the commercial drug substance manufacturer for RVT-801, its recombinant human acid cerami
In November last year, Peregrine Pharmaceuticals called time on its in-house biologics pipeline in favour of focusing on and growing its contract development and biomanufacturing business, Avid Bioservices. Now having dropped the Peregrine name the firm has entered an agreement to sell its phosphatidylserine- targeting programme including lead...
BioArctic AB announced today that the company has received approval by the Estonian State Agency of Medicines, the Estonian Health Board for medical device and the local ethics committee for inclusion of Estonian patients in BioArctic's ongoing clinical Phase 1/ 2 study with SC0806. Our ambition is to develop SC0806 to improve the quality of life f
By a News Reporter-Staff News Editor at Biotech Week BioMarin Pharmaceutical Inc. announced that it presented interim data from a Phase 1/ 2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetylglucosaminidase with a peptide derived from insulin-like growth factor 2, for the trea
By a News Reporter-Staff News Editor at Biotech Week- BiondVax Pharmaceuticals Ltd., developer of a Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, and the European UNISEC consortium announced they will co-host the Annual UNISEC Consortium Meeting, which will take place next week in Jerusalem, Israel.
Sarasota, FL 02/21/2018 Global Bioreactors Market: Overview. Bioreactor or fermenter is requisite equipment required for bioprocessing. Bioreactors are specifically constructed systems or vessels that can support a biologically live environment, as a specific surrounding is required for the cells to grow.
Boston Children`s Hospital, the top ranked pediatric hospital in the nation according to U.S. News and World Report, has joined the TriNetX global health research network to further its efforts at bringing a more data-driven approach to clinical research. "Infusing a data-driven approach into the conversation between research institutions and indu
A new vaccine to prevent hepatitis B in adults has received unanimous recommendation from a Centers for Disease Control and Prevention advisory committee, Dynavax Technologies Corporation announced Wednesday. "With the ACIP's recommendation, Heplisav-B has cleared an important milestone needed to position Dynavax to meet our long-term commercial..
SUMMIT, N.J.- Celgene Corporation today announced that data from the phase III RELIEF clinical trial of OTEZLA in patients with active Behcet's Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology Annual Meeting. OTEZLA is Celgene's oral selective inhibitor of phosphodiesterase 4.
Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that the first patient has been dosed in its Phase 3 VICTORY-1 clinical trial of CNTX-4975, a synthetic, ultra-pure injection of trans-capsaicin, for the treatment of chronic moderate to seve